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Abstract The critical role of the heterogeneous nature of cel-
lular plasma membranes in transmembrane signal transduction
has become increasingly appreciated during the past decade.
Areas of relatively disordered, loosely packed phospholipids
are disrupted by hydrophobic detergent/carbonate-insoluble gly-
colipid-enriched raft microdomains (DIGs) of highly ordered
(glyco)sphingolipids and cholesterol. DIGs exhibit low buoyant
density and are often enriched in glycosylphosphatidylinositol-
anchored plasma membrane proteins (GPI proteins), dually ac-
ylated signalling proteins, such as non-receptor tyrosine kinases
(NRTKs), and caveolin. At least two types of DIGs, hcDIGs
and lcDIGs, can be discriminated on basis of higher and lower
content, respectively, of these typical DIGs components. In qui-
escent di¡erentiated cells, GPI proteins and NRTKs are mainly
associated with hcDIGs, however, in adipose cells certain insu-
lin-mimetic stimuli trigger redistribution of subsets of GPI pro-
teins and NRTKs from hcDIGs to lcDIGs. Presumably, these
stimuli induce displacement of GPI proteins from a GPI recep-
tor located at hcDIGs whereas simultaneously NRTKs dissoci-
ate from a complex with caveolin located at hcDIGs, too.
NRTKs are thereby activated and, in turn, modulate intracellu-
lar signalling pathways, such as stimulation of metabolic insulin
signalling in insulin-sensitive cells. The apparent dynamics of
DIGs may provide a target mechanism for regulating the activ-
ity of lipid-modi¢ed signalling proteins by small drug molecules,
as exempli¢ed by the sulfonylurea, glimepiride, which lowers
blood glucose in an insulin-independent fashion, in part.
* 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Plasma membrane heterogeneity and microdomains
It is currently being recognized that certain transmembrane
signalling functions may be accomplished within compart-
ments present in the plasma membrane as microdomains. Bio-
logical membranes exist in distinct phases, microdomains,
where the concentration of membrane lipids and/or proteins,
as well as their physicochemical properties, are di¡erent from
the surrounding environment [1^3]. ‘Bulk membranes’ are en-
riched in glycerophospholipids (frequently containing unsatu-
rated fatty acids), loosely packed in a liquid-disordered state
and therefore display high £uidity. In contrast, microdomains
have a high content of glycerophospholipids, (glyco)sphingo-
lipids and glycosylphosphatidylinositol (GPI) lipids (both
bearing predominantly saturated fatty acids) as well as cho-
lesterol, tightly packed in a highly-structured liquid-ordered
state [4^6]. Cholesterol is thought to contribute to the tight
packing of lipids in liquid-ordered microdomains by ¢lling
interstitial spaces between other lipid molecules [7,8]. These
characteristics form the basis for resistance of microdomains
toward solubilization by cold non-ionic detergents or alkaline
sodium carbonate as well as their sensitivity toward cholester-
ol depletion by cholesterol-chelating agents or enzymatic cho-
lesterol degradation as has been observed in most but not all
cases studied so far (see below). The insoluble and (often)
cholesterol-dependent membrane subfractions/complexes ex-
hibit low buoyant density during sucrose gradient equilibrium
centrifugation and are now often referred to as glycolipid-
enriched membrane microdomains, detergent-resistant micro-
domains, membrane lipid rafts or detergent/carbonate-insolu-
ble glycolipid-enriched raft microdomains (DIGs) [2,9]. Their
isolation by detergent-free techniques [10^12] proves that they
do not originate from artefacts due to the detergent/carbon-
ate-treatment. Rather, DIGs must have been present in the
membrane before these treatments and assembled as self-or-
ganizing structures [13,14].
2. Microdomains: DIGs and caveolae
DIGs appear to play important roles in intracellular and
transmembrane signalling. A steadily increasing number of
reports demonstrates the (co)assembly of various signalling
proteins at DIGs. Lipid-modi¢ed signalling proteins, among
them (dually) acylated small and heterotrimeric G proteins
and non-receptor tyrosine kinases (NRTKs) as well as GPI-
anchored plasma membrane proteins (GPI proteins) cofrac-
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tionate to a variable extent with (biochemically de¢ned) DIGs
from which they can be coimmunoprecipitated with one an-
other [14^16]. For GPI proteins, colocalization has been con-
¢rmed by monitoring either the preferential partitioning of
£uorescent GPI lipid probes with DIGs vs. bulk membranes
[17,18] or the extensive £uorescence resonance energy transfer
between GPI proteins [19]. Subsequent experimentation pro-
vided preliminary evidence that the packing order of the acyl
chains, rather than their hydrophobicity, represents the pre-
dominant force for targeting lipid-modi¢ed proteins to DIGs
[20]. On basis of these methods, partitioning of GPI proteins,
such as Thy-1, into DIGs was demonstrated without the ne-
cessity of cross-linking.
Caveolae are small £ask-shaped invaginations of the plasma
membrane expressed in most terminally di¡erentiated mam-
malian cell types [6,16]. They are devoid of clathrin coating
and rich in cholesterol and (glyco)sphingolipids [21^24]. Ca-
veolae presumably represent the ‘invaginated type’ of DIGs.
Invagination presumably is driven by the abundant expression
of caveolin 1^3 and £otillin, which ful¢l a structural role
(coating) and can be used as speci¢c markers for caveolae
[14,22]. Caveolae are particularly abundant in adipocytes
and dramatically increase in number in parallel with their
stage of di¡erentiation from ¢broblasts ¢nally accounting
for up to 20% of the cell surface area. Caveolae are involved
in cellular transport processes (endocytosis, transcytosis, po-
tocytosis, cholesterol transport, protein/lipid sorting), which
may involve the recently characterized caveolae^caveosome^
endoplasmic reticulum pathway, as well as in transmembrane
signal transduction [22,24].
3. Microheterogeneity of DIGs
Recent data provide strong evidence for the existence of
two distinct species of DIGs, DIGs of high cholesterol/caveo-
lin content (hcDIGs) and DIGs of low cholesterol/caveolin
content (lcDIGs). hcDIGs are characterized by lower buoyant
density and higher cholesterol content as well as higher en-
richment (vs. bulk plasma membranes) of caveolin and lipid-
modi¢ed signalling proteins compared to lcDIGs which exhib-
it higher buoyant density and lower cholesterol/caveolin/sig-
nalling protein content. Both species coexist in 3T3-L1 ¢bro-
blasts and adipocytes as well as in rat adipocytes. Here, the
major fraction of certain GPI proteins, i.e. GPI-anchored
cAMP-binding ectoprotein-1 (Gce1) and 5P-nucleotidase
(Nuc), as well as of the NRTK, pp59Lyn, is located at hcDIGs
[25]. In addition, the well-documented functional di¡erences
between Ras isoforms, H-Ras and K-Ras, may at least in part
be due to their location at distinct plasma membrane micro-
domains [26,27]. H-Ras preferentially occurs in typical DIGs
and K-Ras in di¡erent microdomains, which also resist solu-
bilization by cold detergent but are insensitive toward choles-
terol depletion. Both H- and K-Ras are prenylated, but H-Ras
is additionally modi¢ed by palmitoylation, whereas K-Ras
contains a basic polylysine sequence. This suggests that car-
boxy-terminal membrane anchors confer targeting speci¢city
for distinct microdomains, i.e. palmitoylation plus prenylation
for hcDIGs and polylysine plus prenylation for lcDIGs [20].
The results of a very recent study are compatible with this
interpretation. Test proteins containing two di¡erent lipid
(myristoyl and palmitoyl) chains became located in typical
DIGs and associated with caveolin [28]. In contrast, test pro-
teins harboring a prenyl (geranylgeranyl) tail were found clus-
tered together in a microdomain species that does not depend
on cholesterol and contains highly disordered lipids capable of
accommodating the irregular structures of the prenyl tail [28].
Furthermore, in a previous morphometric analysis, the cho-
lesterol content of DIGs was varied by the cholesterol-chelat-
ing agent, L-cyclodextrin. Microvillar vesicles from the entero-
cyte brush border membrane were immunogold-labeled and
immunoisolated with antibodies directed toward galectin-4
which represents a marker speci¢c for DIGs [29,30]. These
experiments revealed that a 703% reduction of microvillar
cholesterol does not a¡ect the localization of galectin-4 at
DIGs. In fact, it has been demonstrated that microdomains
can persist in the absence of cholesterol, whereas high choles-
terol levels may even dissolve them [31]. Taken together, these
¢ndings strongly argue for the simultaneous presence of typ-
ical cholesterol-containing DIGs and DIGs of less pro-
nounced or even missing cholesterol dependence. The detailed
biochemical/morphological characterization of the latter, their
identity with adipocyte lcDIGs and their presence in other
di¡erentiated cell types as well as the putative heterogeneity
of caveolae remain to be determined.
4. Caveolin/caveolae signalling hypothesis
Cytoplasmic signalling proteins are targeted to DIGs/ca-
veolae if they are (dually) acylated with long chain saturated
fatty acids (see above). After arrival at DIGs/caveolae, they
may directly interact with caveolin. A speci¢c hydrophobic
20-aa domain within caveolin, the caveolin-sca¡olding do-
main (CSD; aa 82^101 of caveolin-1; see legend to Fig. 2)
has been identi¢ed which interacts with the corresponding
caveolin-binding domain (CBD) of signalling proteins with
high speci¢city [13]. The CBD consensus sequence has been
delineated using a phage display library approach as
PxPxxxxPxxP (P=aromatic aa; x = any aa; see CBD of
pp59Lyn in Fig. 1). Lisanti and coworkers demonstrated in
vitro by using synthetic CSD peptide (CSDP) that the inter-
action between the CSD and the CBD of a signalling protein
keeps this protein in the basal inactive state [13]. In response
to certain stimuli, signalling proteins may be released from
this complex with caveolin and thereby activated as stated
in the so-called caveolin/caveolae signalling hypothesis [22].
Meanwhile convincing evidence has been obtained for opera-
tion of caveolin/caveolae signalling also in vivo in cells (see
below) and animals. In this regard, a cell-permeable peptide
containing the CSD, which interacts with the CBD of endo-
thelial nitric oxide synthase, was found to potently inhibit
acetylcholine-induced vasodilation and nitric oxide produc-
tion in aortic rings and to suppress nitric oxide-mediated vas-
cular compromise in mice treated with proin£ammatory
agents [32]. Furthermore, the ¢ndings that caveolin-1 can
functionally interact with p42/44 mitogen-activated protein
(MAP) kinases in vitro prompted investigations for such a
regulation in the context of oncogenes under experimental
conditions which lead to variations in caveolin-1 expression.
In NIH3T3 cells upon oncogenic transformation with v-Abl
and H-Ras (G12V) oncogenes, caveolin-1 was down-regu-
lated, morphological caveolae were lost and simultaneously
p42/44 MAP kinases were up-regulated [33,34]. Vice versa,
upon heterologous expression of caveolin-1, caveolae were
formed de novo and growth of the transformed cell lines
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became anchorage-dependent accompanied by inactivation of
p42/44 MAP kinases [34].
The recently described generation of mice with a targeted
disruption of the caveolin-1 locus provided ¢rst evidence for
the consequences of caveolin de¢ciency in a mammalian sys-
tem [35]. Mice lacking caveolin-1 were viable and fertile de-
spite complete loss of morphological identi¢able caveolae.
This proved that caveolin-1 is absolutely required for the bio-
genesis of caveolae. Primary ¢broblasts derived from caveolin-
1 null mice proliferated faster than cells from their wild-type
counterparts and had more active cell cycle pro¢les [35]. This
negative regulation of the cell cycle and cell proliferation by
caveolin-1 expression is in line with the caveolin/caveolae-sig-
nalling hypothesis since in caveolin-1 null mice certain cellular
protooncogene products, such as c-Src, c-Myc, Neu tyrosine
kinase [33^34,36], and components of the downstream signal-
ling cascades, such as the Ras-p42/44 MAP kinase cascade,
are no longer negatively controlled by association with ca-
veolin-1. In fact, overexpression of caveolin-1 indicated that
caveolin-1 is a potent inhibitor of the MAP kinase cascade
[37]. Furthermore, antisense-mediated down-regulation of
caveolin-1 in NIH3T3 cells led to hyperactivation and trans-
formation of these cells [38]. Finally, ablation of caveolin ex-
pression in Caenorhabditis elegans via RNAi caused hyperac-
tivation of the meiotic cell cycle, resembling the phenotype of
uncontrolled Ras signalling [39].
5. Insulin signalling via DIGs/caveolae
Insulin receptor signal transduction has been demonstrated
to depend on functional caveolae [40,41]. Lowering of the
cholesterol content in adipocyte plasma membranes by cho-
Fig. 1. Structures of stimuli triggering insulin-mimetic metabolic signalling and action in insulin target cells. PIG(-P) is derived from the lipo-
lytically (by Bacillus cereus PI-speci¢c phospholipase C) and proteolytically (by Staphylococcus aureus V8 protease) cleaved GPI protein, Gce1p,
from Saccharomyces cerevisiae. In consequence, the termini consist of 2P,3P-cyclic phosphoinositol and tripeptidylethanolamidyl moieties; PIG is
derived from PIG(-P) but lacks the tripeptidylethanolamidyl moiety and therefore represents the consensus core glycan head group of GPI pro-
teins as conserved from yeast to man [65]; the sulfonylurea glimepiride is the ingredient of the antidiabetic drug amaryl (trade name); CBDP
(WSFGILLY) is derived from the CBD of human pp59Lyn.
Fig. 2. Hypothetical mechanism for insulin-mimetic signalling via induction of redistribution of signalling proteins between plasma membrane
microdomains (see text for details) for which the term ‘GPI/PIG signalling’ is proposed. Thick uni-directional arrows, redistribution of signal-
ling proteins (GPI proteins and pp59Lyn) from hcDIGs to lcDIGs; thick bi-directional arrows, protein/protein-, protein/lipid- and lipid/lipid-in-
teractions; medium-sized arrows, tyrosine (auto)phosphorylations; thin arrows, molecular targets of insulin-mimetic stimuli (PIG-P, glimepiride,
CBDP) and of inhibitors for redistribution/activation of signalling proteins (sequential trypsin and NaCl treatment, NEM treatment, cholesterol
depletion, CSDP=DGIWKASFTTFTVTKYWFYR); wave-lined arrows, downstream signalling to metabolic e¡ector systems.
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lesterol extraction with L-cyclodextrin or enzymatic cholester-
ol oxidation resulted in loss of the structural integrity of ca-
veolae without cell rupture. This was paralleled by progressive
inhibition of tyrosine phosphorylation of insulin receptor sub-
strate protein (IRS) 1 and activation of glucose transport in
response to insulin although autophosphorylation of the in-
sulin receptor was not impaired [40,41]. Thus, caveolae/DIGs
seem to act as the structural platform required for e⁄cient
coupling of the insulin receptor tyrosine kinase to IRS in
insulin target cells. Recently, a distinct pathway for regulated
translocation of signalling proteins from bulk plasma mem-
branes to DIGs has been elucidated in cultured adipocytes
[42]. The insulin-dependent tyrosine phosphorylation of Cbl
was demonstrated to recruit the APS/CAP/Cbl/CrkII/C3G
multiprotein complex to DIGs where the C3G component
regulates a small GTP-binding protein, TC10, that exclusively
occurs at DIGs. The interaction of the complex with DIGs
and, in consequence, the exposure of Cbl to the insulin recep-
tor (a fraction of which resides in caveolae) relied on speci¢c
binding of the amino-terminal domain of CAP to the DIGs-
resident protein, £otillin [43]. Deletion analysis of the CAP
gene identi¢ed a 115-aa sorbin homology domain responsible
for £otillin binding [44]. Overexpression of a CAP mutant
lacking this domain blocked translocation of the signalling
complex to DIGs and simultaneously abrogated insulin stim-
ulation of glucose transport. These data suggest that in adi-
pocytes at least two types of protein^protein interaction may
determine the targeting of cytoplasmic signalling proteins to
DIGs and their partitioning between DIGs and plasma mem-
branes, (i) interactions between £otillin and the sorbin homol-
ogy domain and (ii) interactions between caveolin and the
CBD. However, the relative importance of the two pathways
for both di¡erential recruitment of signalling proteins to
DIGs and to metabolic insulin signalling in other insulin-re-
sponsive cell types has to be con¢rmed and the molecular
mechanisms of the putative cross-talks to each other as well
as to the insulin signalling cascade remain to be studied.
6. Insulin-mimetic signalling via DIGs
Previous studies have identi¢ed three completely di¡erent
exogenous stimuli (Fig. 1) which induce tyrosine phosphory-
lation of IRS and glucose transport activation in insulin-sen-
sitive target cells. They dispense with the activation of the
insulin receptor, but rather act by triggering redistribution
of signalling components between hcDIGs and lcDIGs.
(i) Synthetic phosphoinositolglycan(-peptides)(PIG(-P)) and
PIG(-P) isolated from natural sources provoke insulin-mi-
metic metabolic actions in insulin-responsive and insulin-re-
sistant adipose and muscle cells in vitro [45^47]. PIG(-P)
are derived from the polar core glycan head group of GPI
proteins. They consist of 2P,3P-cyclic phospho-myo-inositol
coupled to ¢ve sugar residues in typical glycosidic linkages
(PIG portion) and, optionally, contain an additional terminal
ethanolamine-linked tripeptide residue (P portion). In adipo-
cytes isolated from insulin-resistant Zucker fatty rats, PIG(-P)
displayed higher potency in stimulating non-oxidative glucose
metabolism and cell surface expression of the insulin-respon-
sive glucose transporter, GLUT4, than insulin [48]. (ii) The
hypoglycemic sulfonylurea drug, glimepiride, which exerts a
moderate insulin-independent blood glucose-decreasing activ-
ity in type II diabetic animals and patients, has been demon-
strated to induce glucose transport and GLUT4 translocation
in isolated insulin-resistant rat adipocytes. In parallel, tyrosine
phosphorylation of IRS-1/2 and insulin-mimetic regulation
of the typical insulin signalling components downstream of
IRS, such as PI3K, PKB and GSK-3L, were observed [49].
(iii) Introduction of synthetic CBD peptide (CBDP; derived
from pp59Lyn) into isolated rat adipocytes by electroporation
was shown to stimulate tyrosine phosphorylation of IRS-1,
PI3K activity and glucose transport [50].
7. Dynamics of microdomains and GPI/PIG signalling as target
for insulin-mimetic stimuli
In an e¡ort to identify the primary target of PIG(-P) in
insulin target cells, e.g. a putative receptor, we found that
sequential incubation of adipocytes with trypsin and NaCl
or incubation with N-ethylmaleimide (NEM) drastically re-
duced insulin-mimetic signalling and action by PIG(-P)[51].
Reconstitution experiments in which trypsin/NaCl-treated
cells had been reconstituted with the trypsin/NaCl extract
identi¢ed a 115-kDa polypeptide as candidate for the tryp-
sin/NaCl/NEM-sensitive component operating at or upstream
of IRS tyrosine phosphorylation. Subsequent studies demon-
strated speci¢c and saturable binding of radiolabeled PIG-P,
as well as of a radiolabeled and a lipolytically cleaved yeast
GPI protein (harboring the terminal PIG[-P] moiety) to
hcDIGs [52]. Binding to hcDIGs was abolished after inacti-
vation of trypsin/NaCl/NEM-sensitive p115, but considerably
increased after pretreatment of intact adipocytes with (G)PI-
speci¢c phospholipase C. These data suggest that in rat adi-
pocytes insulin-mimetic PIG(-P) are recognized by trypsin/
NaCl/NEM-sensitive p115 located at hcDIGs. p115 might
act as physiological receptor for endogenous ligands, such
as GPI proteins/lipids. A strict correlation has been found
between speci¢c binding of synthetic PIG(-P) derivatives to
the PIG(-P) receptor and their insulin-mimetic signalling/met-
abolic activity [53].
In an e¡ort to identify the primary target of glimepiride in
insulin target cells, for instance a putative receptor, we found
that in intact rat adipocytes or isolated DIGs authentic radio-
labeled glimepiride does not interact speci¢cally with a cell
surface protein but is photo-cross-linked to two distinct GPI
lipid species enriched at hcDIGs in non-saturable fashion
([54] ; N. Hanekop, G. Mu«ller, unpublished data). Apparently,
hydrophilic PIG(-P) and lipophilic glimepiride interact with
hcDIGs of the adipocyte plasma membrane in fundamentally
di¡erent fashion. Presumably, PIG(-P) speci¢cally bind to the
PIG(-P) receptor, whereas glimepiride spontaneously interca-
lates between GPI lipids.
The presence of NRTKs of the Src class in DIGs/caveolae
in insulin target cells and their regulation by caveolin (see
above) raised the possibility that pp59Lyn mediates tyrosine
phosphorylation induced by PIG(-P), glimepiride or CBDP.
In fact, introduction of neutralizing anti-pp59Lyn antibody or
excess of synthetic wildtype CSDP into isolated rat adipocytes
by electroporation blocked IRS-1 and pp59Lyn tyrosine phos-
phorylation and glucose transport activation in response to
PIG(-P)[50]. In agreement with the caveolin/caveolae signal-
ling hypothesis (see above), this may be due to direct binding
of the inhibitory CSDP to the CBD of pp59Lyn and subse-
quent blocking of its activation. In basal adipocytes, caveolin
and pp59Lyn can be coimmunoprecipitated as one complex
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from solubilized DIGs demonstrating their direct interaction
(rather than mere colocalization within DIGs) which keeps
pp59Lyn in the inactive state [55]. Introduction of CBDP
into these adipocytes led to displacement of pp59Lyn (and
also pp125Fak) from caveolin concomitant with increased ty-
rosine phosphorylation of IRS-1, which is presumably based
on relief of pp59Lyn from inhibition by caveolin. Strikingly,
PIG(-P) and glimepiride also induce release of pp59Lyn and
pp125Fak from caveolin at hcDIGs and promote the translo-
cation of the NRTKs to lcDIGs. This is accompanied by re-
distribution of the GPI proteins, Gce1 and Nuc, from hcDIGs
to lcDIGs of the adipocyte plasma membrane [56]. Thus, ac-
tivation of pp59Lyn seems to be based both on its dissociation
from caveolin left at hcDIGs and proper incorporation at
lcDIGs. Disruption of DIGs by cholesterol depletion of the
adipocyte plasma membrane led to almost complete blockade
of PIG(-P)-, glimepiride- and CBDP-induced redistribution of
Gce1, pp125Fak and pp59Lyn from hcDIGs to lcDIGs, tyrosine
phosphorylation of pp59Lyn and IRS-1 as well as activation of
glucose transport. This strongly argues for a causal relation-
ship between these processes [25]. Thus, signalling to IRS by
insulin, PIG(-P), CBDP and glimepiride apparently shares the
involvement of microdomains (hcDIGs, caveolae) and the re-
distribution of signalling proteins between the bulk plasma
membrane and DIGs (insulin) or within DIGs (PIG-[P],
CBDP, glimepiride). However, the molecular mechanisms
which underlie signalling to IRS by these stimuli seem to
di¡er on basis of the di¡erential engagement of pp59Lyn (in
PIG-P, CBDP, glimepiride, but not insulin signalling) and
of trypsin/NaCl/NEM-sensitive p115 (in PIG-P signalling,
only)[25].
8. Hypothetical mechanism for partitioning of GPI proteins
between DIGs and its cross-talk to insulin-mimetic signalling
Targeting of proteins to DIGs is currently assumed to be
based solely on their lipid modi¢cation ([dual] acylation or
glypiation, see above) and to be independent of direct inter-
action with microdomain-resident proteins, such as caveolin
and £otillin [17,57,58]. However, the recent ¢ndings on the
molecular mode of PIG(-P) action suggest a role of the
PIG(-P) receptor in regulating the partitioning of GPI pro-
teins between distinct plasma membrane microdomains: in the
absence of a PIG(-P) receptor, GPI proteins spontaneously
partition between bulk plasma membranes, lcDIGs and
hcDIGs with some preference for lcDIGs (due to their lipid
modi¢cation). This equilibrium is dramatically shifted to
hcDIGs upon speci¢c binding of the PIG(-P) epitope of the
GPI anchor to the PIG(-P) receptor (Fig. 2). In conclusion,
the saturated acyl chains of the GPI anchor seem to be neces-
sary and su⁄cient for accumulation in lcDIGs compared to
bulk membranes. The PIG(-P) moiety of the GPI anchor, on
the other hand, may favor lateral movement of GPI proteins
from lcDIGs to hcDIGs.
The observed redistribution of GPI proteins within DIGs
of the adipocyte plasma membrane in response to PIG(-P),
glimepiride and CBDP can be incorporated into the following
working model for insulin receptor-independent, microdo-
main-dependent insulin-mimetic signalling in insulin target
cells (Fig. 2). (i) PIG(-P) bind as agonists/antagonists to the
PIG(-P) receptor. This protein presumably is identical with
trypsin/NaCl/NEM-sensitive p115 being anchored at the cell
surface via a trypsin-sensitive transmembrane domain and
salt bridges. Upon binding, it displaces those GPI proteins
from the PIG(-P) receptor which are already bound there.
(ii) Glimepiride inserts into DIGs via hydrophobic interac-
tions with GPI lipids thereby altering the structural organiza-
tion of hcDIGs. Both events induce the redistribution of GPI
proteins and NRTKs from hcDIGs to lcDIGs accompanied
by dissociation of the NRTKs from caveolin. (iii) CBDP di-
rectly causes dissociation of pp59Lyn from caveolin (whereas
CSDP binds to and inhibits pp59Lyn). PIG(-P)-, glimepiride-
or CBDP-induced release of pp59Lyn from caveolin/hcDIGs
leads to its activation and to hierarchical phosphorylation of
pp125Fak at Y576/577 (by pp59Lyn) and subsequent autophos-
phorylation of pp125Fak at Y397. After complex formation
with cytoskeletal components (paxillin) and contact to the
extracellular matrix (via integrins and ¢bronectin), pp125Fak
operates as platform molecule presenting IRS-1/2 for tyrosine
phosphorylation by activated pp59Lyn at sites recognized by
the p85 subunit of PI3K and possibly at additional sites. Fur-
thermore, pp59Lyn has been shown to phosphorylate caveolin
(at Y14) and may recognize additional substrates, such as Cbl,
from which IRS/PI3K-independent pathways are initiated. Ul-
timately, activation of IRS/PI3K-dependent and -independent
pathways trigger signalling to the full panel of metabolic in-
sulin e¡ector systems, such as the GLUT4 translocation and
antilipolysis machineries.
9. Communication across the membrane lea£ets of
microdomains
According to the present data, dissociation of the GPI pro-
teins, Gce1 and Nuc, from the PIG(-P) receptor seems to be
obligatorily linked to dissociation of pp59Lyn from its binding
protein, caveolin, enabling parallel movement of GPI proteins
and NRTKs from hcDIGs to lcDIGs. The underlying molec-
ular mechanism remains enigmatic since the acyl groups of
GPI proteins and NRTKs are restricted to the exoplasmic
and cytoplasmic lea£ets, respectively, of the plasma mem-
brane lipid bilayer. It is conceivable that direct contacts be-
tween the fatty acid moieties of (redistributing) GPI proteins
and those of caveolin-associated glycerophospholipids of the
cytoplasmic lea£ets of DIGs generate a signal for caveolin
which causes down-regulation of its binding a⁄nity for
NRTKs. In line with this mechanism, protein^protein inter-
actions between GPI proteins and caveolin or GPI proteins
and pp59Lyn have not been described so far (see also [56]).
Alternatively, the association of caveolin-1 with cholesterol,
which is dependent on its palmitoylation, may link the cyto-
plasmic and exoplasmic lea£ets of the bilayer together. Cho-
lesterol is present in both lea£ets and can potentially form
dimers that span the membrane, acting as a bridge [59].
Thus, caveolin-1 complexed with cholesterol may function
as the postulated linker mediating transmembrane signalling
from GPI proteins to NRTKs which is restricted to DIGs.
This function may also be ful¢lled by other proteolipids, i.e.
microdomain transmembrane adaptor proteins, that contain
palmitoyl groups, such as LAT and PAG [60]. Finally, it
cannot be excluded that redistribution of GPI proteins from
hcDIGs to lcDIGs triggers in pp59Lyn the substitution of pal-
mitate for long chain unsaturated fatty acids impeding its
localization at hcDIGs. A less hydrophobic or less ordered
lipid anchor would be predicted to force acylated proteins
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into less tightly packed microdomains, such as lcDIGs, or the
bulk plasma membrane. This has been demonstrated previ-
ously for the S-acylated NRTK, Fyn, in T cells [61]. A pre-
requisite for operation of this mechanism would be a high
turnover rate of palmitate on pp59Lyn. In fact, this may be
true according to the observation that in Jurkat cells
[3H]palmitate on the NRTK, Lck, has a (relatively short)
half-life of 1^2 h [62]. These ¢ndings together with the reports
that introduction of an unsaturated acyl chain into the G
protein, GKI, [63] and of the heteroatom-substituted palmitic
acid analogue, 13-oxypalmitic acid, into Lck impairs their
association with hcDIGs [62] suggest that the nature of the
fatty acid, by which a signalling protein is modi¢ed, regulates
their partitioning between the distinct microdomains, hcDIGs
and lcDIGs, and the bulk plasma membrane and determines
their ¢nal localization. However, this mechanism leaves unan-
swered the question how redistribution of GPI proteins at the
outer lea£et signals activation to the relevant protein: S-acyl
transferase acting at the inner lea£et. In this regard, it seems
more plausible that the loss of long chain saturated fatty acids
from the outer lea£et caused by the redistribution of GPI
proteins from hcDIGs to lcDIGs simultaneously alters the
fatty acid composition of the microdomains at the inner leaf-
let, too. This ‘adjustment to a common fatty acid milieu’
across the lea£ets of a microdomain may facilitate or be sup-
ported by the redistribution of pp59Lyn from hcDIGs to
lcDIGs. A similar impact of the fatty acid composition on
membrane targeting has been suggested for the displacement
of Src family kinases from microdomains [64].
10. Microdomains and GPI/PIG signalling as targets for
pharmacological intervention
The pathogenesis of type II diabetes and metabolic syn-
drome is characterized by signi¢cant impairment of insulin
signalling downstream of the insulin receptor tyrosine kinase.
In particular, IRS tyrosine phosphorylation and the resulting
activation of PI3K-dependent and -independent pathways in
muscle and adipose cells are severely hampered. Conse-
quently, small drug molecules provoking insulin/insulin recep-
tor-independent tyrosine phosphorylation of IRS via e¡ect-
ing redistribution of GPI proteins and NRTKs between
hc/lcDIGs in insulin target cells may bypass insulin resistance
and thereby lower blood glucose in type II diabetic patients.
Such drugs may be discovered by one of the following strat-
egies, provided the inherent more or less pronounced bottle-
necks can be overcome: (i) blockade of the interaction be-
tween the CBD of pp59Lyn and the CSD has to address the
complex and ill-de¢ned area of protein^protein interactions,
(ii) intercalation into DIGs, as exempli¢ed by glimepiride, has
to ensure speci¢city and involve a stoichiometric rather than
catalytic mechanism, (iii) down-regulation of the PIG(-P) re-
ceptor represents a so-called ‘black box’ (transcription-based)
rather than molecularly de¢ned target and, presumably most
attractive, (iv) agonism/antagonism of the PIG(-P) receptor
o¡ers the advantage of guaranteeing high speci¢city and po-
tency but requires the analysis of large surface areas covered
by protein^glycan interactions. In any case, future antidiabetic
drugs identi¢ed thereby may demonstrate drug-induced redis-
tribution of signalling proteins between plasma membrane
microdomains as a novel and attractive principle for signal
transduction therapy.
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